Open Equity
PRME·

Prime Medicine: Prime Editing Platform With Phase 1/2 CGD Trial + New Zealand Wilson Disease Clearance

NeutralHealthcare / Biotechnology - Gene EditingSmall CapPublished July 8, 2026
View Our Thesis ↓

PRME — 6 Month Price History

Daily OHLC

Executive Summary

Prime Medicine (PRME) gained +8.5% on continued momentum from New Zealand regulatory clearance for PM577 (Wilson Disease) — the first in vivo prime editing trial for Wilson Disease. Phase 1/2 initiation expected H2 2026.

Prime Medicine's proprietary Prime Editing platform is differentiated from CRISPR-Cas9 — it enables precise, targeted gene corrections without creating double-strand DNA breaks, potentially reducing off-target effects. The platform was licensed from the Broad Institute of MIT and Harvard.

Pipeline: PM359 (Phase 1/2, Chronic Granulomatous Disease — data expected 2026), PM577 (Wilson Disease — first in vivo trial clearance, Phase 1/2 H2 2026), PM647 (preclinical). Revenue of $3.18M from collaboration/partnership agreements.

Financial reality: $210.65M annual operating loss ($154M R&D + $56.5M SG&A). Cash runway extends into 2026. At $338M market cap, the stock prices in clinical success that hasn't been demonstrated yet.

Neutral. Legitimate gene editing platform with differentiated technology, but early-stage and cash-burning.

Business Model & Revenue

Prime Medicine, Inc. (NASDAQ: PRME) develops one-time curative genetic therapies using its proprietary Prime Editing gene editing platform. Licensed from Broad Institute. Pipeline: PM359 (CGD, Phase 1/2), PM577 (Wilson Disease, Phase 1/2 H2 2026), PM647 (preclinical). Revenue: $3.18M from collaborations.

Financial Highlights

MetricTTMFY2025FY2024FY2023
Revenue$3.18M$4.63M$2.98M$0
Operating Loss($210.65)M($212.98)M($205.45)M($210M)
R&D$154.18M$160.64M$155.29M$147.91M
SG&A$56.47M$52.35M$50.16M$43.39M
Market Cap~$338M———

Cash runway into 2026. Likely needs capital raise within 12 months.

Competitive Landscape

Gene editing: Intellia (NTLA) — CRISPR-Cas9 in vivo, CRISPR Therapeutics (CRSP) — ex vivo editing, Editas (EDIT) — CRISPR-Cas12a, Beam Therapeutics (BEAM) — base editing. Prime Medicine's differentiator is Prime Editing (precise edits without double-strand breaks). The technology is newer and less validated than CRISPR but potentially safer.

Catalysts

  1. PM359 CGD Phase 1/2 data (expected 2026): First clinical data readout for Prime Editing. Binary event.

  2. PM577 Wilson Disease Phase 1/2 initiation (H2 2026): First in vivo prime editing trial. Dosing and safety data in 2027.

  3. Additional pipeline expansion: Platform can target many genetic diseases with single base edits.

  4. Big pharma partnership: A licensing deal with a major pharma would validate the platform and fund development.

  5. FDA breakthrough therapy designation: If PM359 or PM577 receives BTD, it de-risks the regulatory pathway.

Key Risks

  • $210.65M annual operating loss ($154M R&D + $56.5M SG&A). Cash burn is massive.
  • Cash runway extends into 2026 — capital raise likely within 12 months.
  • Prime Editing technology unproven in clinical settings. No efficacy data yet.
  • Competitive gene editing space: Intellia (NTLA), CRISPR Therapeutics (CRSP), Editas (EDIT), Beam (BEAM).
  • $3.18M revenue from collaborations only. No product revenue.
  • Phase 1/2 CGD data could miss endpoints — binary event risk.

Our Thesis

Prime Editing is a legitimate and potentially transformative gene editing technology. Unlike CRISPR-Cas9 (which cuts both DNA strands), Prime Editing uses a reverse transcriptase and engineered guide RNA to make precise, targeted edits — insertions, deletions, and base substitutions — without double-strand breaks. This reduces the risk of unintended mutations and chromosomal rearrangements.

The Wilson Disease clearance in New Zealand is a real milestone — Prime Medicine is the first company to receive regulatory clearance for an in vivo prime editing trial. CGD Phase 1/2 data expected 2026 will be the first clinical data readout.

The bear case: $210M annual burn rate is massive for a $338M market cap company. Revenue ($3.18M) comes from collaborations, not product sales. Prime Editing has not been clinically validated — the technology works in the lab but in vivo delivery and efficacy are unproven. The gene editing space is competitive (Intellia, CRISPR Therapeutics, Editas, Beam Therapeutics). Cash runway extending into 2026 means a capital raise is likely within 12 months.

Neutral. The science is real but the company is priced for success that hasn't been demonstrated.

Disclaimer: This report is for informational purposes only and does not constitute financial advice. Small-cap, micro-cap, and nano-cap stocks carry significant risk including limited liquidity and higher volatility. Always do your own due diligence before making investment decisions.

Get reports like this delivered free

New small-cap research every week. No paywall, no fluff.